Ergeron Tablet is a pharmaceutical formulation combining Bromelain (90 mg), Trypsin (48 mg), and Rutoside (100 mg), designed to provide anti-inflammatory, proteolytic, and vascular protective effects. Bromelain, a proteolytic enzyme derived from pineapple stems, exhibits potent anti-inflammatory and anti-edematous properties by modulating inflammatory mediators and facilitating the breakdown of fibrin and other proteins involved in tissue injury. Trypsin, a serine protease enzyme, enhances proteolytic activity, promoting the degradation of necrotic tissue and supporting wound healing processes. Rutoside, a bioflavonoid, contributes to capillary stabilization and reduces capillary permeability, thereby improving microcirculation and preventing edema formation. The synergistic action of these components makes Ergeron Tablet effective in managing conditions characterized by inflammation, edema, and impaired microvascular circulation, such as post-traumatic swelling, phlebitis, and chronic venous insufficiency. It is indicated for adjunctive therapy in inflammatory and edematous disorders, particularly where proteolytic enzyme activity and vascular protection are desired. Ergeron Tablet should be administered under medical supervision, with dosage tailored to the severity of the condition and patient response. Caution is advised in patients with hypersensitivity to any component, bleeding disorders, or concurrent anticoagulant therapy.